Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Catheter Precision (NYSE American: VTAK) Announces New LockeT Purchase Order and Expands Sales Team Amid Surge in Trading Volume By: AB Newswire June 18, 2024 at 17:24 PM EDT On June 17, 2024, Catheter Precision, Inc. (NYSE American: VTAK), a US-based leader in electrophysiology medical devices, announced a new purchase order for its latest product, LockeT. In preparation for the nationwide launch of LockeT, the company has recently expanded its US sales and clinical team. Catheter Precision, Inc. (NYSE American: VTAK) has experienced a surge in trading volume over the past few sessions. The stock is performing well relative to key moving averages, including the 20-day ($0.54), 50-day ($0.53), and 200-day ($0.48) averages. Recently, the company's average trading volume has soared to approximately 418,000 shares per day over the past five trading days, compared to a 60-day average of 66,242 shares. This significant increase suggests potential breakout opportunities, making it a stock to watch closely. Following a successful evaluation, Eisenhower Medical Center in Rancho Mirage, California, placed a new purchase order, marking the third California hospital to do so since early May. Additionally, this is the second hospital in the United States to approve orders for future use beyond the evaluation phase. Catheter Precision, a leading U.S.-based medical device company, is committed to providing innovative solutions to hospitals and physicians, enhancing the standard of care. The company focuses on developing groundbreaking technology in collaboration with physicians and continuously improving its products. The company is renowned for its two key innovative products: VIVO™, aiding in ventricular arrhythmia source detection pre-procedure, and LockeT, a closure retention device. Read Entire Update Now! Catheter Precision Inc. (NYSE American: VTAK) was recently featured with other MEME stocks trending tickers: GameStop (NYSE: GME). AMC Entertainment (NYSE: AMC), Novavax Inc. (NASDAQ: NVAX) Dyadic International Inc. (NASDAQ: DYAI) Pesaro Inc. NASDAQ: PRSO Intelligent Bio Solutions Inc (NASDAQ: INBS), among others. Read more. Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.Media ContactCompany Name: The Street ReportsContact Person: EditorEmail: Send EmailCountry: United StatesWebsite: http://www.thestreetreports.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Catheter Precision (NYSE American: VTAK) Announces New LockeT Purchase Order and Expands Sales Team Amid Surge in Trading Volume By: AB Newswire June 18, 2024 at 17:24 PM EDT On June 17, 2024, Catheter Precision, Inc. (NYSE American: VTAK), a US-based leader in electrophysiology medical devices, announced a new purchase order for its latest product, LockeT. In preparation for the nationwide launch of LockeT, the company has recently expanded its US sales and clinical team. Catheter Precision, Inc. (NYSE American: VTAK) has experienced a surge in trading volume over the past few sessions. The stock is performing well relative to key moving averages, including the 20-day ($0.54), 50-day ($0.53), and 200-day ($0.48) averages. Recently, the company's average trading volume has soared to approximately 418,000 shares per day over the past five trading days, compared to a 60-day average of 66,242 shares. This significant increase suggests potential breakout opportunities, making it a stock to watch closely. Following a successful evaluation, Eisenhower Medical Center in Rancho Mirage, California, placed a new purchase order, marking the third California hospital to do so since early May. Additionally, this is the second hospital in the United States to approve orders for future use beyond the evaluation phase. Catheter Precision, a leading U.S.-based medical device company, is committed to providing innovative solutions to hospitals and physicians, enhancing the standard of care. The company focuses on developing groundbreaking technology in collaboration with physicians and continuously improving its products. The company is renowned for its two key innovative products: VIVO™, aiding in ventricular arrhythmia source detection pre-procedure, and LockeT, a closure retention device. Read Entire Update Now! Catheter Precision Inc. (NYSE American: VTAK) was recently featured with other MEME stocks trending tickers: GameStop (NYSE: GME). AMC Entertainment (NYSE: AMC), Novavax Inc. (NASDAQ: NVAX) Dyadic International Inc. (NASDAQ: DYAI) Pesaro Inc. NASDAQ: PRSO Intelligent Bio Solutions Inc (NASDAQ: INBS), among others. Read more. Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.Media ContactCompany Name: The Street ReportsContact Person: EditorEmail: Send EmailCountry: United StatesWebsite: http://www.thestreetreports.com
On June 17, 2024, Catheter Precision, Inc. (NYSE American: VTAK), a US-based leader in electrophysiology medical devices, announced a new purchase order for its latest product, LockeT. In preparation for the nationwide launch of LockeT, the company has recently expanded its US sales and clinical team. Catheter Precision, Inc. (NYSE American: VTAK) has experienced a surge in trading volume over the past few sessions. The stock is performing well relative to key moving averages, including the 20-day ($0.54), 50-day ($0.53), and 200-day ($0.48) averages. Recently, the company's average trading volume has soared to approximately 418,000 shares per day over the past five trading days, compared to a 60-day average of 66,242 shares. This significant increase suggests potential breakout opportunities, making it a stock to watch closely. Following a successful evaluation, Eisenhower Medical Center in Rancho Mirage, California, placed a new purchase order, marking the third California hospital to do so since early May. Additionally, this is the second hospital in the United States to approve orders for future use beyond the evaluation phase. Catheter Precision, a leading U.S.-based medical device company, is committed to providing innovative solutions to hospitals and physicians, enhancing the standard of care. The company focuses on developing groundbreaking technology in collaboration with physicians and continuously improving its products. The company is renowned for its two key innovative products: VIVO™, aiding in ventricular arrhythmia source detection pre-procedure, and LockeT, a closure retention device. Read Entire Update Now! Catheter Precision Inc. (NYSE American: VTAK) was recently featured with other MEME stocks trending tickers: GameStop (NYSE: GME). AMC Entertainment (NYSE: AMC), Novavax Inc. (NASDAQ: NVAX) Dyadic International Inc. (NASDAQ: DYAI) Pesaro Inc. NASDAQ: PRSO Intelligent Bio Solutions Inc (NASDAQ: INBS), among others. Read more. Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.Media ContactCompany Name: The Street ReportsContact Person: EditorEmail: Send EmailCountry: United StatesWebsite: http://www.thestreetreports.com